SCRIBE THERAPEUTICS
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to ground... breaking treatments that will impact millions of lives. Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting. Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
SCRIBE THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Alameda, California, United States
Country:
United States
Website Url:
http://www.scribetx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
120 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Google Apps For Business
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Wellington Management
Wellington Management investment in Series B - Scribe Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - Scribe Therapeutics
Avoro Ventures
Avoro Ventures investment in Series B - Scribe Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series B - Scribe Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Scribe Therapeutics
OrbiMed
OrbiMed investment in Series B - Scribe Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Scribe Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Series B - Scribe Therapeutics
Menlo Ventures
Menlo Ventures investment in Series B - Scribe Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series A - Scribe Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-09 | Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller |
Official Site Inspections
http://www.scribetx.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Scribe Therapeutics"
Scribe → About - scribetx.com
Scribe is rewriting medicine with molecular engineering. Jennifer Doudna is the Li Ka Shing Chancellor's Chair and a Professor in the Departments of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley, as …See details»
Scribe Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s …See details»
Scribe Therapeutics - LinkedIn
Jun 16, 2020 Scribe Therapeutics | 12,826 followers on LinkedIn. CRISPR by Design™ | Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.See details»
Scribe Therapeutics - Overview, News & Similar companies
Mar 14, 2024 www.scribetx.com. Revenue $6 Million. Industry Manufacturing General Manufacturing . Most Recent Scoops. Apr 23 2024. Open Position . Mar 15 2024. Open …See details»
Scribe Therapeutics Presents Data Demonstrating Highly Potent …
May 10, 2024 Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-EdSee details»
Scribe Therapeutics - workinbiotech.com
Scribe Therapeutics is engineering new therapeutics using CRISPR. The underlying causes of many genetic diseases can be treated through gene editing. Scribe is focusing on in vivo …See details»
Company: Scribe Therapeutics - CRISPR Medicine
More than 100 companies to follow in 2023 working with a gene editing tool like CRISPR, TALEN, ZFN, Prime Editor, Base Editor, MegaNuclease...See details»
Scribe
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self …See details»
Scribe Therapeutics (Scribe Therapeutics) - 药物管线_专利_临床试 …
ALAMEDA, Calif.--( BUSINESS WIRE )--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that …See details»
Scribe Therapeutics - Golden
Scribe develops gene-editing therapies based on CRISPR-CasX, an RNA-guided genome-editing platform. The company was founded in 2018 by Jennifer Doudna, Benjamin Oakes, David F. …See details»
Scribe Therapeutics Raises $100M Series B Financing to Further
Mar 31, 2021 To learn more about Scribe’s technology, industry partnership opportunities, and careers, visit www.scribetx.com. About Scribe Therapeutics. Scribe Therapeutics is a …See details»
Scribe → Platform
Discovery. Naturally occurring CRISPR systems have revolutionized genetic medicine since 2012, when their potential for gene editing was unlocked in the lab of our co-founder, Nobel Laureate …See details»
Scribe Therapeutics Unveils Fully Integrated Platform for …
Oct 6, 2020 To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com. Contacts. Thermal for Scribe Therapeutics Kaustuva Das …See details»
Scribe → Scribe Therapeutics Expands Collaboration With Biogen …
May 2, 2022 The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the …See details»
Chief Executive Officer at Scribe Therapeutics - ZoomInfo
Aug 10, 2024 About; Company; Experience; Org Chart; News & Media; Similar Profiles; About Benjamin Oakes Benjamin L. Oakes, PhD, is Co-founder, President, and Chief Executive …See details»
Scribe Achieves Milestone for In Vivo Program in Collaboration …
Apr 28, 2025 Success milestone reached in Scribe and Prevail’s ongoing collaboration to accelerate in vivo therapeutics for neurological and neuromuscular diseases using Scribe’s …See details»
More like this - scribetx.com
May 16, 2023See details»
Scribe Therapeutics Achieves Milestone for In Vivo Program in ...
Jan 13, 2025 Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail …See details»
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome …
May 5, 2025 Organization: PRI Release Summary Scribe to highlight in vivo CRISPR-based genome editing data for Duchenne Muscular Dystrophy at ASGCT 2025, plus joint …See details»
Scribe → Scribe Therapeutics Presents Data on its X-Editing ...
May 19, 2023. Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual MeetingSee details»